Save 30% on Farydak from Europe.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for all European Farydak: Siegfried Barbera, S.L. 1 Ronda de Santa Maria, 158 08210 Barberà del Vallès Barcelona, Spain
Information about Farydak (Panobinostat)
Farydak is an oral medication classified as a histone deacetylase (HDAC) inhibitor. It is primarily used in combination with other therapies for the treatment of multiple myeloma, a type of blood cancer.
Product Highlights
- Treatment of relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone.
- Inhibits histone deacetylases, leading to an accumulation of acetylated histones and disruption of cancer cell growth and survival.
Key Ingredient
Key Benefits
- Improves outcomes when used in combination with other therapies for multiple myeloma.
- May help control the progression of relapsed or refractory disease.
- Convenient dosing in capsule form.
Direction of Use
- Swallow the capsules by mouth, following your healthcare provider's instructions.
- Typically administered on specific days of a treatment cycle, in combination with bortezomib and dexamethasone.
- Follow your healthcare provider's instructions for scheduling and dosage adjustments.
Safety Concerns
- Common side effects may include diarrhea, fatigue, nausea, and thrombocytopenia (low platelet count).
- Monitor for signs of infection due to immunosuppression.
- Regular blood tests are needed to assess blood cell counts and liver function.
Avoid Farydak (Panobinostat) If
- You have a known hypersensitivity to panobinostat or any of its components.
- You have significant liver impairment or active liver disease.
- You are pregnant or planning to become pregnant without consulting a healthcare provider.
- You have a history of significant bleeding disorders or thrombocytopenia.
